Calithera Biosciences Stock Price

-0.21 (-5.77%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Calithera Biosciences Inc CALA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.21 -5.77% 3.43 20:00:00
Close Price Low Price High Price Open Price Previous Close
3.43 3.43 3.715 3.67 3.64
Bid Price Ask Price Spread News
3.43 3.80 0.37 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
3,763 641,682 $ 3.58 $ 2,296,518 548,389 2.45 - 8.18
Last Trade Time Type Quantity Stock Price Currency
16:08:15 50 $ 3.42 USD

Calithera Biosciences Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 242.02M 70.56M 39.36M $ - $ - -1.95 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Calithera Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CALA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.623.823.423.66739,657-0.19-5.25%
1 Month4.144.503.413.71565,081-0.71-17.15%
3 Months5.265.523.414.42566,300-1.83-34.79%
6 Months4.178.183.415.45727,326-0.74-17.75%
1 Year3.918.182.455.19637,477-0.48-12.28%
3 Years16.0018.352.456.27481,732-12.57-78.56%
5 Years6.1320.052.207.58450,391-2.70-44.05%

Calithera Biosciences Description

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm is functioned through the region of US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.